JP2018065821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018065821A5 JP2018065821A5 JP2017218514A JP2017218514A JP2018065821A5 JP 2018065821 A5 JP2018065821 A5 JP 2018065821A5 JP 2017218514 A JP2017218514 A JP 2017218514A JP 2017218514 A JP2017218514 A JP 2017218514A JP 2018065821 A5 JP2018065821 A5 JP 2018065821A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- antigens
- cationic lipid
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 44
- 102000036639 antigens Human genes 0.000 claims 44
- 108091007433 antigens Proteins 0.000 claims 44
- 238000000034 method Methods 0.000 claims 17
- 229960005486 vaccine Drugs 0.000 claims 17
- 239000000693 micelle Substances 0.000 claims 14
- -1 cationic lipid Chemical class 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161533512P | 2011-09-12 | 2011-09-12 | |
| US61/533,512 | 2011-09-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Division JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018065821A JP2018065821A (ja) | 2018-04-26 |
| JP2018065821A5 true JP2018065821A5 (cg-RX-API-DMAC7.html) | 2018-06-28 |
Family
ID=47883670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Active JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
| JP2017218514A Pending JP2018065821A (ja) | 2011-09-12 | 2017-11-13 | 粒子状ワクチン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529976A Active JP6600459B2 (ja) | 2011-09-12 | 2012-09-12 | 粒子状ワクチン製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150110823A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2755680B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6600459B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104066444A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2689799T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2755680T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI673062B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013039989A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| CN102137675A (zh) | 2008-04-17 | 2011-07-27 | Pds生物科技公司 | 通过阳离子脂质的对映体刺激免疫应答 |
| US20150110823A1 (en) * | 2011-09-12 | 2015-04-23 | Pds Biotechnology Corporation | Particulate vaccine formulations |
| JP6348489B2 (ja) | 2012-06-15 | 2018-07-04 | ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | カチオン性脂質ワクチン組成物および使用方法 |
| CA2885741C (en) | 2012-09-21 | 2023-10-17 | Frank Bedu-Addo | Vaccine comprising r-dotap |
| EP3374496A4 (en) | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY |
| WO2018067822A1 (en) * | 2016-10-05 | 2018-04-12 | Pds Biotechnology Corporation | Methods to alter the tumor microenvironment for effective cancer immunotherapy |
| AU2017340407A1 (en) * | 2016-10-05 | 2019-05-02 | Pds Biotechnology Corporation | Novel HPV16 non HLA-restricted T-cell vaccines, compositions and methods of use thereof |
| CA3126544A1 (en) * | 2019-01-12 | 2020-07-16 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| WO2021085696A1 (ko) * | 2019-11-01 | 2021-05-06 | 한국과학기술원 | 작은 지질 나노 입자 및 이를 포함하는 암 백신 |
| WO2023145749A1 (ja) * | 2022-01-27 | 2023-08-03 | 一般財団法人阪大微生物病研究会 | 免疫賦活剤 |
| WO2023203214A1 (en) | 2022-04-22 | 2023-10-26 | Universitat Autònoma De Barcelona | Immunogenic composition with protein micro- and nanoparticles |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6183745B1 (en) * | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
| WO1997003703A1 (en) * | 1995-07-21 | 1997-02-06 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| WO2002060412A2 (en) * | 2001-02-01 | 2002-08-08 | Board Of Regents | Stabilised polymeric aerosols for pulmonary gene delivery |
| US20050031587A1 (en) * | 2002-10-04 | 2005-02-10 | Yamanouchi Pharmaceutical Co., Ltd. | Immune response induction method |
| CA2537900A1 (en) * | 2003-09-03 | 2005-04-28 | Dendritherapeutics, Inc. | Multiplex vaccines |
| CN1559607A (zh) * | 2004-02-20 | 2005-01-05 | �й�ũҵ��ѧ | 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用 |
| US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| US20070059318A1 (en) * | 2005-08-15 | 2007-03-15 | Balu-Iyer Sathy V | Lipid nano particulates containing antigens as cancer vaccines |
| JP5215865B2 (ja) * | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| JP2007238559A (ja) * | 2006-03-10 | 2007-09-20 | Nagoya City Univ | 未成熟樹状細胞活性化剤及びその使用 |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| CN102137675A (zh) * | 2008-04-17 | 2011-07-27 | Pds生物科技公司 | 通过阳离子脂质的对映体刺激免疫应答 |
| WO2011109294A1 (en) * | 2010-03-01 | 2011-09-09 | Dicerna Pharmaceuticals, Inc. | Lipid delivery formulations |
| US20150110823A1 (en) * | 2011-09-12 | 2015-04-23 | Pds Biotechnology Corporation | Particulate vaccine formulations |
-
2012
- 2012-09-12 US US14/344,327 patent/US20150110823A1/en not_active Abandoned
- 2012-09-12 CN CN201280055234.5A patent/CN104066444A/zh active Pending
- 2012-09-12 WO PCT/US2012/054786 patent/WO2013039989A1/en not_active Ceased
- 2012-09-12 JP JP2014529976A patent/JP6600459B2/ja active Active
- 2012-09-12 ES ES12831495.2T patent/ES2689799T3/es active Active
- 2012-09-12 CN CN201910145079.XA patent/CN110075292A/zh active Pending
- 2012-09-12 EP EP12831495.2A patent/EP2755680B1/en active Active
- 2012-09-12 TW TW101133392A patent/TWI673062B/zh active
- 2012-09-12 PL PL12831495T patent/PL2755680T3/pl unknown
-
2017
- 2017-11-13 JP JP2017218514A patent/JP2018065821A/ja active Pending
-
2019
- 2019-03-21 US US16/360,278 patent/US20190275145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018065821A5 (cg-RX-API-DMAC7.html) | ||
| Hess et al. | Phage display as a tool for vaccine and immunotherapy development | |
| Tornesello et al. | Nanoparticles to improve the efficacy of peptide-based cancer vaccines | |
| Serradell et al. | Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins | |
| Zepp | Principles of vaccine design—lessons from nature | |
| Ninomiya et al. | Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice | |
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| Tumban et al. | A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants | |
| Zhang et al. | Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances | |
| JP2014522842A5 (cg-RX-API-DMAC7.html) | ||
| JP2014520807A5 (cg-RX-API-DMAC7.html) | ||
| JP7641005B2 (ja) | コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 | |
| JP2018534304A5 (cg-RX-API-DMAC7.html) | ||
| JP2017035093A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507117A5 (cg-RX-API-DMAC7.html) | ||
| TWI673062B (zh) | 粒狀疫苗調配物 | |
| Mody et al. | Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein | |
| EP4091630A1 (en) | Vaccines comprising r-dotap | |
| Li et al. | Bacteriophage T4 vaccine platform for next-generation influenza vaccine development | |
| JP2011504486A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice | |
| Kianmehr et al. | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice | |
| Patel et al. | Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses | |
| Hendy et al. | Nano/microparticle formulations for universal influenza vaccines | |
| Feng et al. | RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2 |